Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

Ramaswamy Govindan, Li Ding, Malachi Griffith et al. · Cell · 2012 · 1.2K citations · Full text

Medicine, Genetics, Molecular Genetics +12

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Nathan T. Ihle, Lauren A. Byers, Edward S. Kim et al. · JNCI Journal of the National Cancer Institute · 2012 · 529 citations · Full text

Medicine, Genetics, Oncology +17